Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics

References

• AACE Medical guidelines for clinical practice for the management of diabetes mellitus Endocrine Pract 2007 13 Suppl 1 S1 S68
   Google Scholar
• Brez S Rowan M Malcolm J Transition from specialist to primary diabetes care: A qualitative study of perspectives of primary care physicians BMC Fam Pract 2009 6;10 39
   Web of Science ®Google Scholar
• Rolla AR Addressing the need to tailor treatment to the spectrum of type 2 diabetes: New perspectives Diabetes Technol Ther 2009 11 267 274 19425874
   PubMed Web of Science ®Google Scholar
• Action to Control Cardiovascular Risk in Diabetes Study Group (ACCORD) Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 2008 358 2545 2559 18539917
   PubMed Web of Science ®Google Scholar
• ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 2008 358 2560 2572 18539916
   PubMed Web of Science ®Google Scholar
• Duckworth W Abraira C Moritz T VADT Investigators Glucose control and vascular complications in veterans with type 2 diabetes N Engl J Med 2009 360 129 139 19092145
   PubMed Web of Science ®Google Scholar
• Skyler JS Bergenstal R Bonow RO American Diabetes Association; American College of Cardiology Foundation; American Heart Association Intensive glycemic control and the prevention of cardiovascular events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association J Am Coll Cardiol 2009 53 298 304 19147051
   PubMed Web of Science ®Google Scholar
• Meier M Hummel M Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: Moving practice toward evidence-based strategies Vasc Health Risk Manag 2009 5 859 871 19898642
   PubMedGoogle Scholar
• Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes N Engl J Med 2005 353 2643 2653 16371630
   PubMed Web of Science ®Google Scholar
• Holman RR Paul SK Bethel MA Matthews DR Neil HAW 10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 2008 359 1577 1589 18784090
   PubMed Web of Science ®Google Scholar
• Karalliedde J Gnudi L ACCORD and ADVANCE: A tale of two studies on the merits of glycaemic control in type 2 diabetic patients Nephrol Dial Transplant 2008 23 1796 1798 18403430
   PubMed Web of Science ®Google Scholar
• Currie CJ Peters JR Tynan A Survival as a function of HbA(1c) in people with type 2 diabetes: A retrospective cohort study Lancet 2010 375 481 489 20110121
   PubMed Web of Science ®Google Scholar
• Sheldon B Russell-Jones D Wright J Insulin analogues: An example of applied medical science Diabetes Obes Metab 2009 11 5 19 19120431
   PubMed Web of Science ®Google Scholar
• Hemkens LG Grouven U Bender R Risk of malignancies in patients with diabetes treated with human insulins or insulin analogues – a cohort study Diabetologia 2009 52 1745 1754 19588120
   PubMed Web of Science ®Google Scholar
• Colhourn HM SDRN Epidemiology Group Use of insulin glargine and cancer incidence in Scotland: A study from the Scottish Diabetes Research Network Epidemiology Group Diabetologia 2009 52 1755 1765 19603149
   PubMed Web of Science ®Google Scholar
• Currie JM Poole CD Gale EAM The influence of glucose-lowering therapies on cancer risk in type 2 diabetes Diabetologia 2009 52 1766 1777 19572116
   PubMed Web of Science ®Google Scholar
• Jonasson JM Ljung R Talback M Haglund B Gudbjornsdottir S Steineck G Insulin glargine use and short-term incidence of malignancies – a population-based follow-up study in Sweden Diabetologia 2009 52 1745 1754 19588120
   PubMed Web of Science ®Google Scholar
• Home PD Lagarenne P Combined randomised controlled trial experience of malignancies in studies using insulin glargine Diabetologia 2009 52 2499 2506 19756478
   PubMed Web of Science ®Google Scholar
• Dejgaard A Lyngaard H Rastam J Krogsgaard Thomsen M No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: A meta-analysis Diabetologia 2009 52 2507 2512 19838665
   PubMed Web of Science ®Google Scholar
• Smith U Gale EAM Does diabetes therapy influence the risk of cancer? Diabetologia 2009 52 1699 1708 19597799
   PubMed Web of Science ®Google Scholar
• Evans JM Donnelly LA Emslie-Smith AM Alessi DR Morris AD Metformin and reduced risk of cancer in diabetic patients BMJ 2005 330 1304 1305 15849206
   PubMed Web of Science ®Google Scholar
• Libby G Donnelly LA Donnan PT Alessi DR Morris AD Evans JM New users of metformin are at low risk of incident cancer: A cohort study among people with type 2 diabetes Diabetes Care 2009 32 1620 1625 19564453
   PubMed Web of Science ®Google Scholar
• Jiralerspong S Palla SL Giordano SH Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer J Clin Oncol 2009 27 3297 3302 19487376
   PubMed Web of Science ®Google Scholar
• Pollak M Russell-Jones D Insulin analogues and cancer risk: Cause for concern or cause celébre Int J Clin Pract 2010 Feb 26 [Epub ahead of print]
   Web of Science ®Google Scholar
• Devries JH Nattrass M Pieber TR Refining basal insulin therapy: What have we learned in the age of analogues? Diabetes Metab Res Rev 2007 23 441 454 17668418
   PubMed Web of Science ®Google Scholar
• Holman RR Farmer AJ Davies MJ 4-T Study Group Three-year efficacy of complex insulin regimens in type 2 diabetes N Engl J Med 2009 361 1736 1747 19850703
   PubMed Web of Science ®Google Scholar
• Lasserson DS Glasziou P Perera R Holman RR Farmer AJ Optimal insulin regiments in type 2 diabetes mellitus: Systematic review and meta-analyses Diabetologia 2009 52 1990 2000 19644668
   PubMed Web of Science ®Google Scholar
• Heise T Nosek L Ronn BB Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in subjects with type 1 diabetes Diabetes 2004 53 1614 1620 15161770
   PubMed Web of Science ®Google Scholar
• Russell-Jones D Khan R Insulin-associated weight gain in diabetes – causes, effects and coping strategies Diabetes Obes Metab 2007 9 799 812 17924864
   PubMed Web of Science ®Google Scholar
• Owens DR Bolli GB Beyond the era of NPH insulin – long-acting insulin analogs: Chemistry, comparative pharmacology, and clinical application Diabetes Technol Ther 2008 10 333 349 18715209
   PubMed Web of Science ®Google Scholar
• Kurtzhals P Havelund S Jonassen I Markussen J Effect of fatty acids and selected drugs on the albumin binding of a long-acting, acylated insulin analogue J Pharm Sci 1997 86 1365 1368 9423147
   PubMed Web of Science ®Google Scholar
• Havelund S Plum A Ribel U The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin Pharm Res 2004 21 1498 1504 15359587
   PubMed Web of Science ®Google Scholar
• Kurtzhals P Engineering predictability and protraction in a basal insulin analogue: The pharmacology of insulin detemir Int J Obes 2004 28 S23 S28
   Web of Science ®Google Scholar
• Klein O Lynge J Endahl L Damholt B Nosek L Heise T Albumin-bound basal insulin analogues (insulin detemir and NN344): Comparable time-action profiles but less variability than insulin glargine in type 2 diabetes Diabetes Obes Metab 2007 9 290 299 17391154
   PubMed Web of Science ®Google Scholar
• Heise T Pieber TR Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies Diabetes Obes Metab 2007 9 648 659 17645556
   PubMed Web of Science ®Google Scholar
• Bush MA Intensive diabetes therapy and body weight: Focus on insulin detemir Endocrinol Metab Clin North Am 2007 36 Suppl 1 33 44 17881330
   PubMed Web of Science ®Google Scholar
• Hordern SV Wright JE Umpleby AM Shojaee-Moradie F Amiss J Russell-Jones DL Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp Diabetologia 2005 48 420 426 15729576
   PubMed Web of Science ®Google Scholar
• Smeeton F Shojaee Moradie F Jones RH Differential effects of insulin detemir and neutral protamine Hagedorn (NPH) insulin on hepatic glucose production and peripheral glucose uptake during hypoglycaemia in type 1 diabetes Diabetologia 2009 52 2317 2323 19707744
   PubMed Web of Science ®Google Scholar
• Tschritter O Hennige AM Preissl H Cerebrocortical beta activity in overweight humans responds to insulin detemir PLoS ONE 2007 2 e1196 18030331
   PubMed Web of Science ®Google Scholar
• Sharma MD Garber AJ Farmer JA Role of insulin signaling in maintaining energy homeostasis Endocr Pract 2008 14 373 380 18463047
   PubMedGoogle Scholar
• Bohm A Staiger H Hennige AM Haas C Machicao F Hring HU Effect of insulin detemir, compared to human insulin, on 3T3-L1 adipogenesis Regul Pept 2008 151 160 163 18571747
   PubMed Web of Science ®Google Scholar
• Pocock SJ Smeeth L Insulin glargine and malignancy: An unwarranted alarm Lancet 2009 374 511 513 19616841
   PubMed Web of Science ®Google Scholar
• Rosenstock J Fonseca V McGill JB Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: Findings from a 5 year randomised, open-label study Diabetologia 2009 52 1971 1973 19609501
   PubMed Web of Science ®Google Scholar
• Kurtzhals P Schaffer L Sorensen A Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use Diabetes 2000 49 999 1005 10866053
   PubMed Web of Science ®Google Scholar
• Shukla A Grisouard J Ehemann V Hermani A Enzmann H Mayer D Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines Endocr Relat Cancer 2009 16 429 441 19153208
   PubMed Web of Science ®Google Scholar
• Wada T Azegami M Sugiayama M Tsuneki H Sasaoka T Characteristics of signalling properties mediated by long-acting insulin analogue glargine and detemir in target cells of insulin Diab Res Clin Pract 2008 81 269 277
   PubMed Web of Science ®Google Scholar
• Hansen BF Danielsen GM Drejer K Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency Biochem J 1996 315 Pt 1 271 279 8670118
   PubMed Web of Science ®Google Scholar
• Home P Bartley P Russell-Jones DL Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: A randomized clinical trial Diabetes Care 2004 27 1081 1087 15111525
   PubMed Web of Science ®Google Scholar
• Kolendorf K Ross GP Pavlic-Renar I Insulin detemir lowers the risk of hypoglycemia and provides more consistent plasma glucose levels compared with NPH insulin in type 1 diabetes Diabet Med 2006 23 729 735 16842476
   PubMed Web of Science ®Google Scholar
• Pieber TR Draeger E Kristensen A Grill V Comparison of three multiple injection regimens for type 1 diabetes: Morning plus dinner or bedtime administration of insulin detemir vs morning plus bedtime NPH insulin Diabet Med 2005 22 850 857 15975098
   PubMed Web of Science ®Google Scholar
• Pieber TR Treichel HC Hompesch B Comparison of insulin detemir and insulin glargine in subjects with type 1 diabetes using intensive insulin therapy Diabet Med 2007 24 635 642 17381500
   PubMed Web of Science ®Google Scholar
• Russell-Jones DL Simpson R Hylleberg B Draeger E Bolinder J Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type 1 diabetes mellitus using a basal-bolus regimen Clin Ther 2004 26 724 736 15220016
   PubMed Web of Science ®Google Scholar
• Hermansen K Fontaine P Kukolja K Peterkova V Leth G Gall M-A Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes Diabetologia 2004 47 622 629 15298338
   PubMed Web of Science ®Google Scholar
• Bartley PC Bogoev M Larsen J Philotheou A Long-term efficacy and safety of insulin detemir compared to neutral protamine Hagedorn insulin in patients with type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: A 2-year, randomized, controlled trial Diabet Med 2008 25 442 449 18387078
   PubMed Web of Science ®Google Scholar
• Le Floch JP Lévy M Mosnier-Pudar H the ADAPT™ Study Group A comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: The ADAPT™ Study Diabetes Care 2009 32 32 37 18945928
   PubMed Web of Science ®Google Scholar
• Robertson KJ Schoenle E Gucev Z Mordhorst L Gall MA Ludvigsson J Insulin detemir compared with NPH insulin in children and adolescents with type 1 diabetes Diabet Med 2007 24 27 34 17227321
   PubMed Web of Science ®Google Scholar
• Braun D Konrad D Lang-Muritano M Schoenle E Improved glycemic control and lower frequency of severe hypoglycemia with insulin detemir; long-term experience in 105 children and adolescents with type 1 diabetes Pediatr Diabetes 2008 9 4 pt 2 382 387 18331413
   PubMed Web of Science ®Google Scholar
• Robertson KJ Schonle E Gucev Z Benefits of insulin detemir over NPH insulin in children and adolescents with type 1 diabetes: Lower and more predictable fasting plasma glucose and lower risk of nocturnal hypoglycemia Diabetes 2004 53 A144
   Web of Science ®Google Scholar
• Heller S Koenen C Bode B Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: A 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial Clin Ther 2009 31 2086 2097 19922879
   PubMed Web of Science ®Google Scholar
• Garber AJ Clauson P Pedersen CB Kølendorf K Lower risk of hypoglycemia with insulin detemir than with neutral protamine Hagedorn insulin in older persons with type 2 diabetes: A pooled analysis of phase III trials J Am Geriatr Soc 2007 55 1735 1740 17979896
   PubMed Web of Science ®Google Scholar
• Hermansen K Davies M Derezinski T Martinez G Clauson P Home P A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes Diabetes Care 2006 29 1269 1274 16732007
   PubMed Web of Science ®Google Scholar
• Rosenstock J Davies M Home PD Larsen J Tamer SC Schernthaner G Insulin detemir added to oral anti-diabetic drugs in type 2 diabetes provides glycemic control comparable to insulin glargine with less weight gain Diabetes 2006 55 A132
   Web of Science ®Google Scholar
• Haak T Tiengo A Draeger E Suntum M Waldhausl W Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes Diabetes Obes Metab 2005 7 56 64 15642076
   PubMed Web of Science ®Google Scholar
• Raslova K Bogoev M Raz I Leth G Gall M-A Hancu N Insulin detemir and insulin aspart: A promising basal-bolus regimen for type 2 diabetes Diabetes Res Clin Pract 2004 66 193 201 15533587
   PubMed Web of Science ®Google Scholar
• Philis-Tsimikas A Charpentier G Clauson P Ravn GM Roberts VL Thorsteinsson B Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes Clin Ther 2006 28 1569 1581 17157113
   PubMed Web of Science ®Google Scholar
• Rosenstock J Davies M Home PD Larsen J Koenen C Schernthaner G A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes Diabetologia 2008 51 408 416 18204830
   PubMed Web of Science ®Google Scholar
• Hollander P Cooper J Bregnhøj J Pedersen CB A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes Clin Ther 2008 30 1976 1987 19108786
   PubMed Web of Science ®Google Scholar
• Home P Kurtzhals P Insulin detemir: From concept to clinical experience Expert Opin Pharmacother 2006 7 325 343 16448327
   PubMed Web of Science ®Google Scholar
• Danne T Datz N Endahl L Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: Results from a randomized, double-blind, controlled trial Pediatr Diabetes 2008 9 554 560 18761644
   PubMed Web of Science ®Google Scholar
• Monnier L Colette C Mas E Regulation of oxidative stress by glycaemic control: Evidence for an independent inhibitory effect of insulin therapy Diabetologia 2010 53 562 571 19890623
   PubMed Web of Science ®Google Scholar
• Monnier L Mas E Ginet C Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes JAMA 2006 295 1681 1687 16609090
   PubMed Web of Science ®Google Scholar
• Ceriello A Esposito K Piconi L Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients Diabetes 2008 57 1349 1354 18299315
   PubMed Web of Science ®Google Scholar
• Brownlee M Hirsch IB Glycemic variability: A hemoglobin A1c-independent risk factor for diabetic complications JAMA 2006 295 1707 1708 16609094
   PubMed Web of Science ®Google Scholar
• Lachin JM Genuth S Nathan DM Zinman B Rutledge BN DCCT/EDIC Research Group Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial revisited Diabetes 2008 57 995 1001 18223010
   PubMed Web of Science ®Google Scholar
• Kilpatrick ES Rigby AS Atkin SL Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes Diabetes Care 2009 32 1901 1903 19549736
   PubMed Web of Science ®Google Scholar
• Niskanen L Virkamäki A Hansen JB Saukkonen T Fasting plasma glucose variability as a marker of nocturnal hypoglycemia in diabetes: Evidence from the PREDICTIVE™ study Diabetes Res Clin Pract 2009 86 e15 e18 19747748
   PubMedGoogle Scholar
• Meneghini L Liebl A Abrahamson M Insulin detemir: A historical perspective on a modern basal analogue insulin Prim Care Diabetes 2010 4 1 S31 S42 20394890
   PubMedGoogle Scholar
• Raslová K Tamer SC Clauson P Karl D Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index Clin Drug Investig 2007 27 279 285
   PubMed Web of Science ®Google Scholar
• Philis-Tsimikas A Tolerability, safety and adherence to treatment with insulin detemir injection in the treatment of type 2 diabetes Patient Prefer Adherence 2008 2 323 332 19920979
   PubMedGoogle Scholar
• Dornhorst A Lüddeke HJ Koenen C PREDICTIVE Study Group Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE Diabetes Obes Metab 2008 10 75 81 18034846
   PubMed Web of Science ®Google Scholar
• Dornhorst A Lüddeke HJ Sreenan S PREDICTIVE Study Group Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: Subgroup analysis from the PREDICTIVE study Int J Clin Pract 2008 62 659 665 18324957
   PubMed Web of Science ®Google Scholar
• Eeg-Olofsson K Cederholm J Nilsson PM Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: An observational study in 13,087 patients Diabetologia 2009 52 65 73 18985314
   PubMed Web of Science ®Google Scholar
• Anderson JW Konz EC Obesity and disease management: Effects of weight loss on comorbid conditions Obes Res 2001 9 Suppl 4 326S 334S 11707561
   PubMedGoogle Scholar
• Fledelius C Damgaard J Vinterby A Ribel U Petersen JS Insulin detemir results in less body weight and fat mass increase than both NPH and insulin glargine in the ZDF rat Presented at: 68th annual meeting of the American Diabetes Association 2008 June 6–10 San Francisco, California Poster 497
   Google Scholar
• Tinahones FJ Martin M Cardona F Macias-Gonzalez M Visceral fat mass in patients with type 2 diabetes is reduced during insulin detemirbased basal bolus therapy, whereas it is increased during NPH-insulin based basal bolus therapy Obesity & Metabolism 2008 4 165 168
   Web of Science ®Google Scholar
• Mandosi E Fallarino M Rossetti M Gatti A Morano S Waist circumference reduction after insulin detemir therapy in type 2 diabetes patients previously treated with NPH Diabetes Res Clin Pract 2009 84 e18 e20 19297054
   PubMedGoogle Scholar
• Polonsky KS Gumbiner B Ostrega D Griver K Tager H Henry RR Alterations in immunoreactive proinsulin and insulin clearance induced by weight loss in NIDDM Diabetes 1994 43 871 877 8013750
   PubMed Web of Science ®Google Scholar
• Bryden KS Neil A Mayou RA Peveler RC Fairburn CG Dunger DB Eating habits, body weight, and insulin misuse. A longitudinal study of teenagers and young adults with type 1 diabetes Diabetes Care 1999 22 1956 1960 10587825
   PubMed Web of Science ®Google Scholar
• Herpertz S Albus C Wagener R Comorbidity of diabetes and eating disorders. Does diabetes control reflect disturbed eating behavior? Diabetes Care 1998 21 1110 1116 9653604
   PubMed Web of Science ®Google Scholar
• Reaven G Metabolic syndrome. Pathophysiology and implications for management of cardiovascular diseases Circulation 2002 106 286 288 12119239
   PubMed Web of Science ®Google Scholar
• Grundy SM Brewer B Cleeman JI Smith SC Lenfant C Defintion of metabolic syndrome. Report of the National Heart Lung and Blood Institute/American Heart Association Conference on scientific issues related to definition Circulation 2004 109 433 438 14744958
   PubMed Web of Science ®Google Scholar
• Dornhorst A Luddeke H-J Sreenan S PREDICTIVE Study Group Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort Int J Clin Pract 2007 61 523 528 17313628
   PubMed Web of Science ®Google Scholar
• Dornhorst A Lüddeke HJ Honka M PREDICTIVE Study Group Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study Curr Med Res Opin 2008 24 369 376 18096110
   PubMed Web of Science ®Google Scholar
• Sreenan S Virkamki A Zhang K Hansen JB PREDICTIVE study group Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: Data from the European cohort of the PREDICTIVE study Int J Clin Pract 2008 62 1971 1980 19166444
   PubMed Web of Science ®Google Scholar
• Yenigun M Honka M Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: Results from a subgroup of the PREDICTIVE study Int J Clin Pract 2009 63 425 432 19222627
   PubMed Web of Science ®Google Scholar
• Kurtoglu S Atabek ME Dizdarer C Pirgon O Isguven P Emek S PREDICTIVE Turkey Study Group Insulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: Findings from the Turkish cohort of the PREDICTIVE observational study Pediatr Diabetes 2009 10 401 407 19220776
   PubMed Web of Science ®Google Scholar
• Meneghini L Koenen C Weng W Selam JL The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemirin patients with type 2 diabetes – results of the randomized, controlled PREDICTIVE 303 study Diabetes Obes Metab 2007 9 902 913 17924873
   PubMed Web of Science ®Google Scholar
• Meneghini LF Rosenberg KH Koenen C Merilainen MJ Luddeke H-J Insulin detemir improves glycemic control with less hypoglycemia and no weight gain in patients with type 2 diabetes who were insulin naïve or treated with NPH or insulin glargine: Clinical practice experience from a German subgroup of the PREDICTIVE study Diabetes Obes Metab 2007 9 418 427 17391170
   PubMed Web of Science ®Google Scholar
• Meneghini LF Dornhorst A Sreenan S PREDICTIVE Study Group Once-daily insulin detemir in a cohort of insulin-naïve patients with type 2 diabetes: A sub-analysis from the PREDICTIVE study Curr Med Res Opin 2009 25 1029 1035 19281426
   PubMed Web of Science ®Google Scholar
• Knerr I Hofer SE Holterhus PM Prevailing therapeutic regimes and predictive factors for prandial insulin substitution in 26,687 children and adolescents with type 1 diabetes in Germany and Austria Diabet Med 2007 24 1478 1481 17971184
   PubMed Web of Science ®Google Scholar
• Honka M Results of the PREDICTIVE project in the Czech Republic Vnitr Lek 2008 54 361 367 Czech 18630615
   PubMedGoogle Scholar
• Philips JC Scheen AJ Insulin detemir in the predictive study: Results in patients with type 1 diabetes in the Belgian cohort Rev Med Liege 2009 64 124 130 French 19418931
   PubMedGoogle Scholar
• Plank J Bodenlenz M Sinner F A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir Diabetes Care 2005 28 1107 1112 15855574
   PubMed Web of Science ®Google Scholar
• Riddle MC Rosenstock J Gerich J Insulin Glargine 4002 Study Investigators The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients Diabetes Care 2003 26 3080 3086 14578243
   PubMed Web of Science ®Google Scholar
• Bruce DG Chisholm DJ Storlien LH Kraegen EW Physiological importance of deficiency in early prandial insulin secretion in noninsulin- dependent diabetes Diabetes 1988 37 736 744 3289994
   PubMed Web of Science ®Google Scholar
• Ashwell SG Gebbie J Home PD Twice-daily compared with once-daily insulin glargine in people with type 1 diabetes using mealtime insulin aspart Diabet Med 2006 23 879 886 16911626
   PubMed Web of Science ®Google Scholar
• Clement S Bowen-Wright H Twenty-four hour action of insulin glargine (Lantus) may be too short for once-daily dosing: A case report Diabetes Care 2002 25 1479 1480 12145255
   PubMed Web of Science ®Google Scholar
• Fontaine P Gin H Pinget M Effect of insulin detemir dose frequency on clinical outcomes in patients with diabetes in PREDICTIVE Adv Ther 2009 26 535 551 19513632
   PubMed Web of Science ®Google Scholar
• Blonde L Merilainen M Karwe V Raskin P TITRATE Study Group Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: An assessment of two different fasting plasma glucose targets – the TITRATE study Diabetes Obes Metab 2009 11 623 631 19515182
   PubMed Web of Science ®Google Scholar
• Selam JL Koenen C Weng W Meneghini L Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naïve patients with type 2 diabetes: A subgroup analysis of the US PREDICTIVE 303 study Curr Med Res Opin 2008 24 11 20 18021495
   PubMed Web of Science ®Google Scholar
• Selam JL Meneghini LF Basal-bolus therapy with insulin detemir using the 303 algorithm in the US PREDICTIVE 303 trial Adv Ther 2009 26 194 207 19259629
   PubMed Web of Science ®Google Scholar
• Fu AZ Qiu Y Radican L Impact of fear of insulin or fear of injection on treatment outcomes of patients with diabetes Curr Med Res Opin 2009 25 1413 1420 19422281
   PubMed Web of Science ®Google Scholar
• Cramer JA A systematic review of adherence with medications for diabetes Diabetes Care 2004 27 1218 1224 15111553
   PubMed Web of Science ®Google Scholar
• Peyrot M Rubin RR Lauritzen T International DAWN Advisory Panel Resistance to insulin therapy among patients and providers: Results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study Diabetes Care 2005 28 2673 2679 16249538
   PubMed Web of Science ®Google Scholar
• Brod M Kongsø JH Lessard S Christensen TL Psychological insulin resistance: Patient beliefs and implications for diabetes management Qual Life Res 2009 18 23 32 19039679
   PubMed Web of Science ®Google Scholar
• Goldstein HH Pen devices to improve patient adherence with insulin therapy in type 2 diabetes Postgrad Med 2008 120 172 179 18824835
   PubMed Web of Science ®Google Scholar
• Hänel H Weise A Sun W Pfützner JW Thomé N Pfützner A Differences in the dose accuracy of insulin pens J Diabetes Sci Technol 2008 2 478 481 19885213
   PubMedGoogle Scholar
• Hartman I Insulin analogs: Impact on treatment success, satisfaction, quality of life, and adherence Clin Med Res 2008 6 54 67 18801953
   PubMedGoogle Scholar
• Kerney DL Paradis D Brunton S Patient perceptions of insulin detemir as reported through patient telephone surveys Curr Med Res Opin 2007 23 2043 2049 17640448
   PubMed Web of Science ®Google Scholar
• Preumont V Buysschaert M De Beukelaer S Mathieu C Insulin detemir in routine clinical practice: A 26-week follow-up in type 1 diabetic patients from the Belgian PREDICTIVE Cohort Acta Clin Belg 2009 64 49 55 19317241
   PubMed Web of Science ®Google Scholar
• Valentine WJ Palmer AJ Erny-Albrecht KM Cost-effectiveness of basal insulin from a US health system perspective: Comparative analyses of detemir, glargine, and NPH Adv Ther 2006 23 191 207 16751153
   PubMed Web of Science ®Google Scholar
• Gschwend MH Mark Aagren M Valentine MJ Cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in five European countries J Med Econ 2009 12 114 123 19545216
   PubMedGoogle Scholar
• Tunis SL Minshall ME Conner C Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian paying setting: Modeling analysis Curr Med Res Opin 2009 25 1273 1284 19366302
   PubMed Web of Science ®Google Scholar
• Palmer AJ Valentine WJ Ray JA An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UK Curr Med Res Opin 2007 23 895 901 17407646
   PubMed Web of Science ®Google Scholar
• Valentine WJ Erny-Albrecht KM Ray JA Roze S Cobden D Palmer AJ Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: A modeling study of cost-effectiveness in the United States Adv Ther 2007 24 273 290 17565917
   PubMed Web of Science ®Google Scholar
• Valentine WJ Goodall G Aagren M Nielsen S Palmer AJ Erny-Albrecht K Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: A modelling study of long-term clinical and cost outcomes Adv Ther 2008 25 567 584 18568451
   PubMed Web of Science ®Google Scholar